These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34371524)

  • 1. Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist.
    Gehin M; Wierdak J; Sabattini G; Sidharta PN; Dingemanse J
    Br J Clin Pharmacol; 2022 Feb; 88(2):810-819. PubMed ID: 34371524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects.
    Zenklusen I; Dingemanse J; Reh C; Gehin M; Kaufmann P
    Drugs R D; 2024 Mar; 24(1):97-108. PubMed ID: 38472696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
    Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
    Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin.
    Zenklusen I; Muehlan C; Ulc I; Liška J; Dingemanse J
    Clin Exp Pharmacol Physiol; 2020 Nov; 47(11):1843-1849. PubMed ID: 32603512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment.
    Berger B; Muehlan C; Klein G; Dingemanse J
    Clin Transl Sci; 2021 Nov; 14(6):2132-2138. PubMed ID: 34121345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
    Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
    Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects.
    Berger B; Kornberger R; Dingemanse J
    Eur Neuropsychopharmacol; 2021 Oct; 51():90-104. PubMed ID: 34098518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis.
    Schilling U; Henrich A; Muehlan C; Krause A; Dingemanse J; Ufer M
    Clin Drug Investig; 2021 Aug; 41(8):711-721. PubMed ID: 34331678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.
    Berger B; Brooks S; Zuiker R; Richard M; Muehlan C; Dingemanse J
    CNS Drugs; 2020 Dec; 34(12):1253-1266. PubMed ID: 33205362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.
    Hu L; Dou T; Sun Q; Tang L; Cai M; Qian W; Wang H
    Invest New Drugs; 2023 Apr; 41(2):276-283. PubMed ID: 36800130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies.
    Boof ML; Alatrach A; Ufer M; Dingemanse J
    Eur J Clin Pharmacol; 2019 Feb; 75(2):195-205. PubMed ID: 30284597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea.
    Boof ML; Dingemanse J; Lederer K; Fietze I; Ufer M
    Sleep; 2021 Jun; 44(6):. PubMed ID: 33305817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
    Ogasawara K; Kam J; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):369-377. PubMed ID: 34019108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
    Ufer M; Kelsh D; Schoedel KA; Dingemanse J
    Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea.
    Boof ML; Ufer M; Fietze I; Pépin JL; Guern AS; Lemoine V; Dingemanse J
    Sleep Med; 2022 Apr; 92():4-11. PubMed ID: 35306405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease.
    Boof ML; Dingemanse J; Brunke M; Esselmann A; Heymer P; Kestermann O; Lederer K; Fietze I; Ufer M
    J Sleep Res; 2021 Aug; 30(4):e13248. PubMed ID: 33417730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daridorexant for the treatment of insomnia disorder: findings and implications.
    Dos Santos JBR; da Silva MRR
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1749-1761. PubMed ID: 36098753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia.
    Najib J; Toderika Y; Dima L
    Am J Ther; 2023 Jul-Aug 01; 30(4):e360-e368. PubMed ID: 37449930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.